News

Milan Zdravkovic, Senior Vice President, Chief Medical Officer, and Head of Research & Development at Sobi, said: “Sobi has a long-term commitment to improve the lives for people

With this expanded capacity, Arven will support local healthcare needs by bringing biopharmaceuticals to the Turkish and surrounding markets faster, whilst also opening up European markets through the

The priority review status will reduce the review clock to six months from the standard 10 months. Even though the action date is not specified, it is expected

After constructive negotiations with several regulators including the US Food and Drug Administration and European Medicines Agency, Summit said it will design a trial intended at assessing the superiority of ridinilazole over the

The first-in-man clinical trial utilizes a single intravenous injection of AAV gene therapy for patients with MPS IIIA (Sanfilippo syndrome type A), a devastating lysosomal storage disease that

This study, which will enroll 40 healthy adults in U.S. sites, follows a successful Phase 1a single ascending dose clinical study completed in 2016. Preclinical studies have shown

The IND is now active and Audentes plans to initiate VALENS, the multicenter, multinational, open-label, ascending dose phase 1 / 2 clinical study of AT342. Preliminary data from

Xyzal is a single daily dose oral antihistamine, with an active ingredient of levocetirizine dihydrochloride that relieves runny nose, sneezing, itchy watery eyes and itching of the nose

The assets acquired have been developed by Cantab Anti Infectives Ltd, a PBB group company. Ankit Mahadevia, M.D., Chief Executive Officer of Spero, said: “The acquisition of these